Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions

• Published in: Journal of antimicrobial chemotherapy Vol. 79; no. 5; pp. 1169 - 1175
• Main Authors: Bergmann, Felix, Wölfl-Duchek, Michael, Jorda, Anselm, Al Jalali, Valentin, Leutzendorff, Amelie, Sanz-Codina, Maria, Gompelmann, Daniela, Trimmel, Karin, Weber, Maria, Eberl, Sabine, Van Os, Wisse, Minichmayr, Iris K, Reiter, Birgit, Stimpfl, Thomas, Idzko, Marco, Zeitlinger, Markus
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 02.05.2024
• Subjects: Adult; Antifungal Agents - administration & dosage; Antifungal Agents - pharmacokinetics; Aspergillus flavus - drug effects; Aspergillus fumigatus - drug effects; Bronchoalveolar Lavage Fluid - chemistry; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - metabolism; Male; Microbial Sensitivity Tests; Middle Aged; Nitriles - administration & dosage; Nitriles - pharmacokinetics; Original Research; Prospective Studies; Pyridines - administration & dosage; Pyridines - pharmacokinetics; Triazoles - administration & dosage; Triazoles - pharmacokinetics; Young Adult
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkae088

Invasive aspergillosis is a severe fungal infection that affects multiple organ systems including the CNS and the lungs. Isavuconazole, a novel triazole antifungal agent, has demonstrated promising activity against Aspergillus spp. However, data on the penetration of isavuconazole into the CNS and ELF and intracellular accumulation remain limited. We conducted a prospective single-centre pharmacokinetic (PK) study in 12 healthy volunteers. Subjects received seven doses of 200 mg isavuconazole to achieve an assumed steady-state. After the first and final infusion, plasma sampling was conducted over 8 and 12 h, respectively. All subjects underwent one lumbar puncture and bronchoalveolar lavage, at either 2, 6 or 12 h post-infusion of the final dose. PBMCs were collected in six subjects from blood to determine intracellular isavuconazole concentrations at 6, 8 or 12 h. The AUC/MIC was calculated for an MIC value of 1 mg/L, which marks the EUCAST susceptibility breakpoint for Aspergillus fumigatus and Aspergillus flavus. C max and AUC0-24h of isavuconazole in plasma under assumed steady-state conditions were 6.57 ± 1.68 mg/L (mean ± SD) and 106 ± 32.1 h·mg/L, respectively. The average concentrations measured in CSF, ELF and in PBMCs were 0.07 ± 0.03, 0.94 ± 0.46 and 27.1 ± 17.8 mg/L, respectively. The AUC/MIC in plasma, CSF, ELF and in PBMCs under steady-state conditions were 106 ± 32.1, 1.68 ± 0.72, 22.6 ± 11.0 and 650 ± 426 mg·h/L, respectively. Isavuconazole demonstrated moderate penetration into ELF, low penetrability into CSF and high accumulation in PBMCs. Current dosing regimens resulted in sufficient plasma exposure in all subjects to treat isolates with MICs ≤ 1 mg/L.